Table I.
Patient characteristics at baseline (modified intent-to-treat population).*
| Guaifenesin/pseudoephedrine (n = 591) | Placebo (n = 588) | |
|---|---|---|
| Age, y | 37.4 (13.7) | 38.8 (13.7) |
| Female sex | 395 (66.8) | 404 (68.7) |
| Race | ||
| White | 494 (83.6) | 485 (82.5) |
| Black/African American | 59 (10.0) | 63 (10.7) |
| Other | 38 (6.4) | 40 (6.8) |
| Diagnosis | ||
| Acute bronchitis | 66 (11.2) | 68 (11.6) |
| Acute sinusitis | 145 (24.5) | 151 (25.7) |
| Rhinitis | 62 (10.5) | 67 (11.4) |
| Nasal congestion | 87 (14.7) | 70 (11.9) |
| Chest congestion | 22 (3.7) | 24 (4.1) |
| Other | 209 (35.4) | 208 (35.4) |
| Baseline total symptom score | 23.4 (4.9) | 23.6 (4.5) |
| Baseline individual symptom scores | ||
| Chest congestion | 3.05 (1.14) | 3.11 (1.11) |
| Thickened mucus | 3.50 (0.90) | 3.49 (0.80) |
| Nasal congestion | 3.55 (0.92) | 3.57 (0.92) |
| Runny nose | 2.93 (1.23) | 3.01 (1.14) |
| Sinus headache | 3.11 (1.35) | 3.11 (1.30) |
| Sinus pressure | 3.39 (1.09) | 3.36 (1.10) |
| Postnasal drip | 3.11 (1.16) | 3.15 (1.07) |
| Baseline WURSS-21 score | ||
| Overall total | 90.4† (22.1) | 91.2 (21.0) |
| Symptom score | 44.0† (10.7) | 44.3 (10.0) |
| Functional score | 36.2† (12.9) | 36.7 (12.6) |
WURSS-21 = Wisconsin Upper Respiratory Symptom Survey.
⁎
Values are presented as mean (SD) (age, baseline total symptom score, baseline individual symptom scores, and baseline WURSS-21 score), or n (%) (sex, race, and diagnosis).
†
n = 590.